FDA Approves Moderna's mRNA Seasonal Flu Vaccine for Adults 50+
The FDA has granted approval for Moderna's mRNA seasonal flu vaccine, branded as mFLUSIVA, making it available for all adults ages 50 and older. The vaccine's regulatory journey proved unusual—the agency initially declined to review the application before ultimately granting approval.
mFLUSIVA represents Moderna's entry into the seasonal flu vaccine market using messenger RNA technology, the same platform approach the company employed for its COVID-19 vaccine. The approval marks a milestone for mRNA-based vaccines beyond the pandemic context, though the shot still underwent a notably bumpy path through the regulatory process before receiving the green light.